Shuttle Pharmaceuticals
SHPH
5 hedge funds and large institutions have $169K invested in Shuttle Pharmaceuticals in 2026 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
56% less capital inflows, than outflows
Capital inflows: $148K | Capital outflows: $337K
64.12% less ownership
Funds ownership: 65% → 0.88% (-64%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$69.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$52.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$20.6K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$4.93K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HRT Financial
New York
|
-$255K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$79.2K |
| 3 |
Barclays
London,
United Kingdom
|
-$2.44K |
SHPH Hedge Fund Activity: Q3 2026 in Review
5 of the 8,114 institutional investors tracked by Wall St. Rank reported a position in Shuttle Pharmaceuticals (SHPH) for Q3 2026, worth a combined $169K — down 50% from $338K a quarter earlier.
Fund positioning in SHPH was balanced in Q3 2026: 3 funds opened new positions, 3 closed out, 1 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $69.8K. The largest seller was HRT Financial, exiting entirely with an estimated $255K sold.
- 5 institutional investors held Shuttle Pharmaceuticals (SHPH) as of Q3 2026, unchanged from Q2 2026.
- Funds reported $169K of Shuttle Pharmaceuticals stock for Q3 2026, down 50% quarter-over-quarter.
- 3 funds opened new Shuttle Pharmaceuticals positions in Q3 2026 and 3 closed out, a net change of 0 holders.
- The largest Shuttle Pharmaceuticals buyer in Q3 2026 was Jane Street, an estimated $69.8K added.
- The largest Shuttle Pharmaceuticals seller in Q3 2026 was HRT Financial, an estimated $255K sold.
Based on aggregated 13F filings for Q3 2026.